Loading
A phase 1/2 trial of VRN110755 in non-small-cell lung cancer and small-cell lung cancer, run by Voronoi, Inc, now recruiting.
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07699328 by Voronoi, Inc, with 315 participants planned, started 2024-03-26 and due to reach its primary completion in 2029-01-01. Interventions recorded: VRN110755. Conditions listed: EGFR-Mutant Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.